Molecular Imaging of Healing After Myocardial Infarction

Current Cardiovascular Imaging Reports

Volumn 4, Issue 1, 2011, Pages 63-76

  Naresh, Nivedita K ^a   Ben Mordechai, Tamar ^b   Leor, Jonathan ^b   Epstein, Frederick H ^a,c  

^a University of Virginia   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Infarct healing; Molecular imaging; Myocardial infarction

Indexed keywords

EID: 84857628062     PISSN: 19419066     EISSN: 19419074     Source Type: Journal    
DOI: 10.1007/s12410-010-9058-0     Document Type: Review

References (49)

1. Lloyd-Jones D, Adams RJ, Brown TM et al.: Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121(7): e46-e215.
2. Leor J, Amsalem Y, Cohen S: Cells, scaffolds, and molecules for myocardial tissue engineering. Pharmacol Ther 2005, 105(2): 151-63.
3. Frangogiannis NG: The immune system and cardiac repair. Pharmacol Res 2008, 58(2): 88-111.
4. Nahrendorf M, Pittet MJ, Swirski FK: Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circulation 2010, 121(22): 2437-45.
5. Frantz S, Bauersachs J, Ertl G: Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovasc Res 2009, 81(3): 474-81.
6. Mann DL, Bogaev R, Buckberg GD: Cardiac remodelling and myocardial recovery: lost in translation? Eur J Heart Fail 2010, 12(8): 789-96.
7. Shah AM, Solomon SD: A unified view of ventricular remodelling. Eur J Heart Fail 2010, 12(8): 779-81.
8. Frey B, Gaipl US: The immune functions of phosphatidylserine in membranes of dying cells and microvesicles. Semin Immunopathol 2010.
9. 99mTc-labeled HYNIC-cys-annexin A5 as an apoptosis imaging agent. Bioorg Med Chem Lett 2008, 18(13): 3794-8.
10. Hofstra L, Liem IH, Dumont EA et al.: Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet 2000, 356(9225): 209-12.
11. Sarda-Mantel L, Michel JB, Rouzet F et al.: (99 m)Tc-annexin V and (111)In-antimyosin antibody uptake in experimental myocardial infarction in rats. Eur J Nucl Med Mol Imaging 2006, 33(3): 239-45.
12. Dumont EA, Reutelingsperger CP, Smits JF et al.: Real-time imaging of apoptotic cell-membrane changes at the single-cell level in the beating murine heart. Nat Med 2001, 7(12): 1352-5.
13. Sosnovik DE, Schellenberger EA, Nahrendorf M et al.: Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magneto-optical nanoparticle. Magn Reson Med 2005, 54(3): 718-24.
14. 99mTc-labeled C2A domain of synaptotagmin I in a porcine ischemia-reperfusion model. Nucl Med Biol 2007, 34(8): 917-23.
15. 99mTc-labeled duramycin as a novel phosphatidylethanolamine-binding molecular probe. J Nucl Med 2008, 49(8): 1345-52.
16. 111In-antimyosin-antibodies after ischemia-reperfusion in rats. Eur J Nucl Med Mol Imaging 2008, 35(1): 158-65. This article describes the time course of apoptosis and necrosis using SPECT.
17. • Sosnovik DE, Garanger E, Aikawa E et al.: Molecular MRI of cardiomyocyte apoptosis with simultaneous delayed-enhancement MRI distinguishes apoptotic and necrotic myocytes in vivo: potential for midmyocardial salvage in acute ischemia. Circ Cardiovasc Imaging 2009, 2(6): 460-7. This article describes a novel method to image apoptosis and necrosis post-MI in vivo using MRI.
18. Sosnovik DE, Nahrendorf M, Deliolanis N et al.: Fluorescence tomography and magnetic resonance imaging of myocardial macrophage infiltration in infarcted myocardium in vivo. Circulation 2007, 115(11): 1384-91.
19. Flogel U, Ding Z, Hardung H et al.: In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. Circulation 2008, 118(2): 140-8.
20. Leor J, Rozen L, Zuloff-Shani A et al.: Ex vivo activated human macrophages improve healing, remodeling, and function of the infarcted heart. Circulation 2006, 114(1 Suppl): I94-100.
21. Montet-Abou K, Daire JL, Hyacinthe JN et al.: In vivo labelling of resting monocytes in the reticuloendothelial system with fluorescent iron oxide nanoparticles prior to injury reveals that they are mobilized to infarcted myocardium. Eur Heart J 2010, 31(11): 1410-20. This article demonstrates using MRI with iron-oxide particles to assess the infiltration of monocytes in MI. The monocytes were labeled prior to MI.
22. Yang Y, Yang Y, Yanasak N, Schumacher A, Hu TC: Temporal and noninvasive monitoring of inflammatory-cell infiltration to myocardial infarction sites using micrometer-sized iron oxide particles. Magn Reson Med 2010, 63(1): 33-40.
23. Yang F, Liu YH, Yang XP, Xu J, Kapke A, Carretero OA: Myocardial infarction and cardiac remodelling in mice. Exp Physiol 2002, 87(5): 547-55.
24. Vandervelde S, van Amerongen MJ, Tio RA, Petersen AH, van Luyn MJ, Harmsen MC: Increased inflammatory response and neovascularization in reperfused vs. non-reperfused murine myocardial infarction. Cardiovasc Pathol 2006, 15(2): 83-90.
25. 1-Mapping and Gd-Liposomes [Abstract]. Circulation 2010, In press.
26. Xu Y, Klibanov AL, Beyers RJ et al.: Abstract 3364: Serial MRI Assessment of Macrophage Activity in the Murine Heart after Myocardial Infarction using Gadolinium-labeled Liposomes as a Positive Contrast Agent. Circulation 2007, 116(16_MeetingAbstracts): II.
27. Nahrendorf M, Swirski FK, Aikawa E et al.: The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 2007, 204(12): 3037-47.
28. highmacrophages on infarct healing and post-MI remodeling.
29. • Nahrendorf M, Sosnovik D, Chen JW et al.: Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury. Circulation 2008, 117(9): 1153-60. This article demonstrates the time course of myeloperoxidase post-MI in vivo using serial MRI.
30. Heymans S, Luttun A, Nuyens D et al.: Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 1999, 5(10): 1135-42.
31. Vasilyev N, Williams T, Brennan ML et al.: Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction. Circulation 2005, 112(18): 2812-20.
32. Meoli DF, Sadeghi MM, Krassilnikova S et al.: Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J Clin Invest 2004, 113(12): 1684-91.
33. 3integrin to assess the time course of post-MI angiogenesis using PET.
34. • Rodriguez-Porcel M, Cai W, Gheysens O et al.: Imaging of VEGF receptor in a rat myocardial infarction model using PET. J Nucl Med 2008, 49(4): 667-73. This article describes imaging post-MI angiogenesis by PET with targeting VEGF.
35. 99mTc-RAFT-RGD. J Nucl Cardiol 2010, 17(3): 435-43.
36. vintegrins for studying the role of IGF-1 in infarct healing and LV remodeling.
37. Oostendorp M, Douma K, Wagenaar A et al.: Molecular magnetic resonance imaging of myocardial angiogenesis after acute myocardial infarction. Circulation 2010, 121(6): 775-83.
38. Dobaczewski M, Gonzalez-Quesada C, Frangogiannis NG: The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J Mol Cell Cardiol 2010, 48(3): 504-11.
39. Su H, Spinale FG, Dobrucki LW et al.: Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation 2005, 112(20): 3157-67.
40. Chen J, Tung CH, Allport JR, Chen S, Weissleder R, Huang PL: Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction. Circulation 2005, 111(14): 1800-5.
41. • Helm PA, Caravan P, French BA et al.: Postinfarction myocardial scarring in mice: molecular MR imaging with use of a collagen-targeting contrast agent. Radiology 2008, 247(3): 788-96. This article presents molecular MRI of myocardial scar post-MI using a collagen-targeting contrast agent.
42. Caravan P, Das B, Dumas S et al.: Collagen-targeted MRI contrast agent for molecular imaging of fibrosis. Angew Chem Int Ed Engl 2007, 46(43): 8171-3.
43. Muzard J, Sarda-Mantel L, Loyau S et al.: Non-invasive molecular imaging of fibrosis using a collagen-targeted peptidomimetic of the platelet collagen receptor glycoprotein VI. PLoS One 2009, 4(5): e5585.
44. 111In Fab fragment of monoclonal antibody specific for tenascin-C. Int Heart J 2008, 49(4): 481-92. This article demonstrates targeted SPECT imaging of tenascin-C post-MI.
45. 125I-anti-tenascin-C antibody imaging. J Nucl Med 2010, 51(7): 1116-22.
46. van den Borne SW, Isobe S, Verjans JW et al.: Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction. J Am Coll Cardiol 2008, 52(24): 2017-28.
47. Nahrendorf M, Hu K, Frantz S et al.: Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodeling in mice with myocardial infarction. Circulation 2006, 113(9): 1196-202.
48. • Nahrendorf M, Aikawa E, Figueiredo JL et al.: Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction. Eur Heart J 2008, 29(4): 445-54. This article demonstrates the effects of FXIII on infarct healing and LV remodeling in vivo using SPECT-CT.
49. Jugdutt BI: Limiting fibrosis after myocardial infarction. N Engl J Med 2009, 360(15): 1567-9.